Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

A new oral medication, Orforglipron, is set to revolutionize weight loss and diabetes management, offering a pill alternative ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

A daily pill to help people newly diagnosed with type 1 diabetes, or those at risk of developing it, live without the ...

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli ...

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Eli Lilly’s stock jumps as Zepbound sales nearly triple at lower prices Trial underway in $40 million lawsuit filed by a ...

The number of medications in development to treat obesity continues to grow, and the drugs can offer health benefits for ...